Xttrium Labs' Exidine
Executive SummaryFirm is petitioning FDA for three years marketing exclusivity for its Exidine antimicrobial cleansing agent (chlorhexidine gluconate 2% and 2.5% solution). Xttrium says its products, approved in December, are entitled to exclusivity because FDA required clinical investigations for approval. Xttrium noted that the studies, glove juice and health care personnel hand washing, "had never been previously used in the drug approval process" for chlorhexidine products.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.